Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00416949 · ClinicalTrials.gov registry record · NA
Iodine I 131 in Treating Patients With Thyroid Cancer
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT00416949: Clinical Trial NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00416949 is a NA study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00416949, a NA study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
Primary Outcome
Tumor absorbed doses (Gy) calculated using patient-specific dosimetry.
Interventions
- DEVICE Patient-specific dosimetry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-10 |
| Phase | NA |
Why NCT00416949 stopped before completion
NCT00416949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Patient-specific dosimetry is the first listed.
NCT00416949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00416949 about?
NCT00416949 is a clinical study titled "Iodine I 131 in Treating Patients With Thyroid Cancer". RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
What is the current status of trial NCT00416949?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2006-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00416949?
The interventions under investigation include: Patient-specific dosimetry (DEVICE).
Who is sponsoring clinical trial NCT00416949?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00416949's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia